title: Intravenously injected radiolabelled fatty acids image brain tumour phospholipids in vivo: differential uptakes of palmitate, arachidonate and docosahexaenoate.
abstract: This paper investigates the incorporation of intravenously (i.v.) administered radiolabelled fatty acids--[9,10(3)-H]palmitate (3H-PA), [1-14C]arachidonate (14C-AA) and [1-14C]docosahexaenoate (14C-DHA)--into intracerebrally implanted tumours in awake Fischer-344 rats. A suspension of Walker 256 carcinosarcoma tumour cells (1 x 10(6) cells) was implanted into the right cerebral hemisphere of 8- to 9-week-old rats. Seven days after implantation, the awake rat was infused i.v. for 5 min with 3H-PA (6.4 mCi/kg), 14C-AA (170 microCi/kg) or 14C-DHA (100 microCi/kg). Twenty minutes after the start of infusion, the rat was killed and coronal brain sections were obtained for quantitative autoradiography and histology. Each fatty acid showed well-demarcated incorporation into tumour tissue. Areas of necrosis or haemorrhage showed no or small levels of incorporation. The ratios of incorporation into the tumour to incorporation into contralateral brain regions were 2.8-5.5 for 3H-PA, 2.1-3.3 for 14C-AA and 1.5-2.2 for 14C-DHA. The mean ratios differed significantly between the fatty acids (P < 0.01). 3H-PA was not incorporated into necrotic tumours despite the presence of an open blood-tumour barrier, indicated by extravasated horseradish peroxidase. The incorporation rate constant of 3H-PA was similar for small intracerebral and large extracerebral tumours. The results show that 3H-PA, 14C-AA and 14C-DHA are incorporated more readily into tumour tissue than into brain, and that the increase is primarily due to increased utilization of fatty acids by tumour cells and not due to a high blood-tumour permeability. The relative increases in rates of incorporation for the different fatty acids may be related to lipid composition of the tumour and to the requirement of and specific role of these fatty acids in tumour cell growth and division.
authors.affiliation: Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892.
authors.forename: T
authors.initials: T
authors.lastname: Nariai
authors.forename: N H
authors.initials: NH
authors.lastname: Greig
authors.forename: J J
authors.initials: JJ
authors.lastname: DeGeorge
authors.forename: S
authors.initials: S
authors.lastname: Genka
authors.forename: S I
authors.initials: SI
authors.lastname: Rapoport
mesh_terms: D000818:Animals; D016718:Arachidonic Acid / Q000493:pharmacokinetics; D001345:Autoradiography; D001812:Blood-Brain Barrier / Q000502:physiology; D001932:Brain Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism*; D002250:Carbon Radioisotopes; D004281:Docosahexaenoic Acids / Q000493:pharmacokinetics; D005227:Fatty Acids / Q000097:blood / Q000493:pharmacokinetics*; D007275:Injections, Intravenous; D008297:Male; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000493:pharmacokinetics; D010743:Phospholipids / Q000378:metabolism*; D011877:Radionuclide Imaging; D051381:Rats; D011916:Rats, Inbred F344; D014316:Tritium
chemical_list: D002250:Carbon Radioisotopes; D005227:Fatty Acids; D010169:Palmitic Acids; D010743:Phospholipids; D014316:Tritium; D004281:Docosahexaenoic Acids; D016718:Arachidonic Acid; D019308:Palmitic Acid